| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
HIV-1 integrase (IN). The compound binds the integrase-DNA complex and inhibits the strand transfer reaction by chelating the two Mg²⁺ ions in the enzyme’s active site, preventing the 3′-processing and strand transfer steps of retroviral integration.
|
|---|---|
| ln Vitro |
Drug compounds have been modified to include stable heavy isotopes of carbon, hydrogen, and other elements, mostly as tracers for quantification throughout the drug development process. Due to its potential to impact a drug's pharmacokinetic and metabolic characteristics, deuteration has drawn attention[1].
Raltegravir sodium inhibits HIV-1 integrase strand transfer with an IC50 of 2–7 nM in cell-free assays using purified enzyme. It is active against a broad panel of HIV-1 isolates, including non-B subtypes and circulating recombinant forms, with IC50 values ranging from 5 to 12 nM. It is essentially inactive against HCV polymerase and HIV reverse transcriptase (IC50 > 50 μM). |
| ln Vivo |
Raltegravir induces viro-immunological improvement of nonhuman primates with progressing SIVmac251 infection. One
non-human primate shows an undetectable viral load following Raltegravir monotherapy[5].
Raltegravir is clinically approved for HIV-1 infection and is effective in treatment-naive and treatment-experienced patients. In animal models, it reduces viral load and prevents integration in HIV-infected humanized mice or SIV-infected macaques. Its pharmacokinetics and safety are well characterized in clinical use. |
| Enzyme Assay |
In vitro integrase strand transfer assays use recombinant HIV-1 integrase assembled on a radiolabeled or fluorescent oligonucleotide substrate. Compound is serially diluted and pre-incubated with the integrase-DNA complex before addition of the target DNA. Strand transfer products are separated by gel electrophoresis and quantified by autoradiography or fluorescence, and IC50 values are calculated.
|
| Cell Assay |
In vitro antiviral assays use HIV-1-infected cells (e.g., MT-4, PBMC, or TZM-bl reporter cells) treated with serial dilutions of raltegravir sodium. Viral replication is quantified by p24 ELISA, luciferase reporter activity, or qPCR after 4–7 days, and IC50 values are calculated. Cytotoxicity is assessed in parallel.
|
| Animal Protocol |
In vivo animal experiments use HIV-infected humanized mice or SIV-infected macaques. Raltegravir sodium is administered orally or intravenously at doses guided by pharmacokinetic studies. Efficacy is assessed by plasma viral load, CD4⁺ T-cell counts, and proviral DNA integration in tissues, compared with vehicle-treated controls.
|
| References |
| Molecular Formula |
C20H20FKN6O5
|
|---|---|
| Molecular Weight |
482.506708145142
|
| Exact Mass |
485.13
|
| CAS # |
1246816-98-7
|
| Related CAS # |
Raltegravir potassium;871038-72-1
|
| PubChem CID |
46782845
|
| Appearance |
Typically exists as solid at room temperature
|
| tPSA |
153
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
33
|
| Complexity |
843
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1C(C(=O)NCc2ccc(F)cc2)=C([O-])C(=O)N(C)C=1C(C)(C)NC(=O)c1oc(C)nn1.[K+]
|
| InChi Key |
IFUKBHBISRAZTF-NXIGQQGZSA-M
|
| InChi Code |
InChI=1S/C20H21FN6O5.K/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11;/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30);/q;+1/p-1/i4D3;
|
| Chemical Name |
potassium;4-[(4-fluorophenyl)methylcarbamoyl]-2-[2-[(5-methyl-1,3,4-oxadiazole-2-carbonyl)amino]propan-2-yl]-6-oxo-1-(trideuteriomethyl)pyrimidin-5-olate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0725 mL | 10.3625 mL | 20.7250 mL | |
| 5 mM | 0.4145 mL | 2.0725 mL | 4.1450 mL | |
| 10 mM | 0.2072 mL | 1.0362 mL | 2.0725 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.